ReviewNature reviews. Cancer2018
Inflammatory breast cancer biology: the tumour microenvironment is key.
Review in Nature reviews. Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 194 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
194 citing papers in PubMed, 1 synthesis or guideline pooled it, 335 citations in OpenAlex.
- The prognostic impact of systemic inflammation and nutritional indicators on targeted therapy for renal cell carcinoma: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.ESMO open · 2025Trial
- Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Clinicopathological factors associated with brain metastases development among breast cancer patients receiving neoadjuvant chemotherapy.Journal of neuro-oncology · 2026Article
- Reprogramming the Immune Landscape of Inflammatory Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Metabolic maintenance of breast cancer cells and metastases through E-cadherin/YAP-dependent pyruvate carboxylase expression.bioRxiv : the preprint server for biology · 2026Article
- Soluble E-cadherin-CXCL1-CXCR2 axis as a therapeutic vulnerability in inflammatory breast cancer brain metastasis.Neuro-oncology · 2026Article
- Integrative QSP Modeling of Cancer Stem Cells in Triple-Negative Breast Cancer: Impacts on Tumor Immunity and Response to Immune Checkpoint Inhibitors.CPT: pharmacometrics & systems pharmacology · 2026Article
- Tumor Extracellular Vesicles lncOSLMT Drives Lung Inflammatory Premetastatic Niche Formation in Osteosarcoma via mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Estrogen receptor β target gene expression reveals novel repressive functions in aggressive breast cancer.NPJ breast cancer · 2026Article
- The spatial immune landscape predicts outcome and reveals the central role of tumor-associated macrophages in inflammatory breast cancer biology.Breast cancer research : BCR · 2026Article
- Article
- Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database.Breast cancer research and treatment · 2025Article
- Glutamate promotes CCL2 expression to recruit tumor-associated macrophages by restraining EZH2-mediated histone methylation in hepatocellular carcinoma.Oncoimmunology · 2025Article
- Impact of Postpartum Diagnosis on Survival of Women with Inflammatory Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Inhibition of DDX3 modulates immune signaling in aggressive breast cancers.Cancer letters · 2025Article
- Review
- Exome sequencing reveals new insights into the germline landscape of inflammatory breast cancer among Tunisian patients.Journal of translational medicine · 2025Article
- ASO Author Reflections: Postpartum Diagnosis of Stage IV Inflammatory Breast Cancer.Annals of surgical oncology · 2025Article
- Investigating the Prognostic Impact of Postpartum Diagnosis in Women with De Novo Stage IV Inflammatory Breast Cancer.Annals of surgical oncology · 2025Article
134 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Inflammatory breast cancer (IBC) is a rare and aggressive disease that accounts for ~2-4% of all breast cancers. However, despite its low incidence rate, IBC is responsible for 7-10% of breast cancer-related mortality in Western countries. Thus, the discovery of robust biological targets and the development of more effective therapeutics in IBC are crucial. Despite major international efforts to understand IBC biology, genomic studies have not led to the discovery of distinct biological mechanisms in IBC that can be translated into novel therapeutic strategies. In this Review, we discuss these molecular profiling efforts and highlight other important aspects of IBC biology. We present the intrinsic characteristics of IBC, including stemness, metastatic potential and hormone receptor positivity; the extrinsic features of the IBC tumour microenvironment (TME), including various constituent cell types; and lastly, the communication between these intrinsic and extrinsic components. We summarize the latest perspectives on the key biological features of IBC, with particular emphasis on the TME as an important contributor to the aggressive nature of IBC. On the basis of the current understanding of IBC, we hope to develop the next generation of translational studies, which will lead to much-needed survival improvements in patients with this deadly disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.